BAG6 (also known as BAT3/Scythe) is a ubiquitin-like protein that is thought to participate in a variety of seemingly unrelated physiological and pathological processes, such as apoptosis, antigen presentation and the T-cell response. Recent studies have shown that BAG6 is essential for the quality control of aggregation-prone polypeptide biogenesis. It forms part of a complex that determines the fate of newly synthesized client proteins for membrane insertion, ubiquitin-mediated degradation and/or aggregate formation. A biologically relevant transmembrane protein family has recently been shown to be a major client of BAG6, suggesting that many of the known diverse BAG6 functions can be interpreted by BAG6-mediated control of membrane protein biogenesis. In this review, we summarize the current understanding of the physiological roles of BAG6 with a particular focus on quality control for nascent chain polypeptides.
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Abbreviations: ALIS, aggresome-like induced structures; BAG, bcl-2-associated athanogene; BAT3, HLA-B-associated transcript 3; CCT, chaperonincontaining t-complex polypeptide 1; DRiPs, defective ribosomal products; E3, ubiquitin ligase; ECI, evolutionally conserved island; ER, endoplasmic reticulum; ERAD, ER-associated protein degradation; Get, guided entry of tail-anchored; IFN, interferon; Luc163, truncated luciferase with N-terminal 163 residues; MHC, major histocompatibility complex; MG-132, benzoyl-Leu-Leu-Leu-aldehyde; MS, mass spectrometry; NLS, nuclear localization signal; SRP, signal recognition particle; TA, tail-anchored; TCRa, T-cell receptor a; Tim-3, T-cell immunoglobulin and mucin domain-containing molecule-3; TMD, transmembrane domain; TRC, TMD recognition complex; TRiC, TCP-1 ring complex; UBL, ubiquitin-like; UPS, ubiquitinproteasome system. Folding of newly synthesized polypeptides is supported by a number of molecular chaperones (1) , including members of the heat shock protein family and the cytoplasmic chaperonin tailless complex polypeptide-1 ring complex (TRiC)/CCT, which modulate protein aggregation and suppress its cytotoxicity (24) . Despite the presence of many chaperones that assist nascent polypeptides in folding and assembly, accumulating evidence suggests that some newly synthesized polypeptides are produced with aberrant structures so are targeted for degradation immediately after their synthesis (5, 6) . Protein misfolding is induced by a variety of physiological and pathological conditions such as heat stress, incomplete translational termination, post-translational assembly failure and defects in messenger RNA splicing. Recognition of aberrant structures should be essential for the rapid elimination of misfolded and/or misassembled proteins. For example, hydrophobic residues that are normally buried in native-folded proteins tend to be exposed by protein misfolding/misassembly and act as degradation signals, 'degron' (7, 8) , delivering the misfolded proteins to the ubiquitinproteasome system (UPS) for degradation (9) . However, the mechanisms behind this remain elusive.
Bcl-2-associated athanogene 6 (BAG6) was originally identified as a novel gene product encoded within the class III region of the human major histocompatibility complex (MHC, Fig. 1 ) and is alternatively designated BAT3 (HLA-B-associated transcript 3) (10). Human BAG6/BAT3 is a large protein of 1,132 residues that contains a ubiquitin-like (UBL) domain at its N-terminus and a BAG-family domain at the C-terminus (Fig. 2AC ). BAG6 is a relatively conserved protein in vertebrates with the human protein sharing 57% amino acid sequence identity with Xenopus laevis (frog). Related bag6 genes can be found in the genome of invertebrates such as arthropods, echinodermats and coelenterates, although the functions of these have not been studied. In addition, it should be noted that the genome of yeast Saccharomyces cerevisiae lacks a bag6 homologous gene. Tissue and developmental expression of mammalian BAG6 is universal, although some tissues including the testis, brain and lymphoid organ seem to express more BAG6 than others (1316). A number of seemingly unrelated functions of BAG6 have been reported, including the control of apoptosis (15, 1719) , signal transduction (20, 21) , cell cycle progression (22, 23) , antigen presentation (16) and the T-cell response (24) . Because the reported roles of vertebrate BAG6 are so diverse, a coordinate understanding of its physiological significance has been limited until recently.
We identified BAG6 as a novel recognition factor for a series of aggregation-prone hydrophobic substrates in mammalian cells (16) . Furthermore, BAG6 plays a crucial role in the metabolism of newly synthesized defective and/or mislocalized proteins (16, 2527) . In a series of recent studies, unexpected functions of BAG6 in the quality control of transmembrane protein assembly have successively been reported (2532), giving rise to the possibility that its proposed functions could be interpreted from the viewpoint of protein biogenesis. In this review, we will therefore summarize the current advances in our understanding of BAG6 and attempt to give a conceptual framework in which to fit our present knowledge on the functions mediating the protein quality control of nascent chain polypeptides.
BAG6 Is Essential for the Elimination of Aggregation-Prone Nascent Chain Polypeptides
We originally identified BAG6 as a novel binding partner of the products of an aberrant splicing variant of Rpn10c, a proteasome ubiquitin receptor subunit (33) . Although N-terminal UBL domains of BAG6 are necessary for Rpn10c binding, the ubiquitinbinding ability of Rpn10c is dispensable for BAG6 binding. Instead, the hydrophobic region specific to the spliced variant of Rpn10c protein is necessary and sufficient for BAG6 interaction (33) . This implies that hydrophobicity is a preferential recognition signal for BAG6. Subsequently, our mass spectrometry (MS)-based analysis re-identified BAG6 as a CL1-degron-binding protein in vivo (16) . CL1-degron is encoded by an alternatively spliced and frame-shifted sequence of the yeast PMD1 gene and is characterized by its exposed hydrophobic C-terminal region, which is essential for its intrinsic degron potency (79) . Indeed, BAG6 is essential for the proteasome-mediated degradation of the EGFP-CL1 fusion protein in mammalian cells (16) .
Treatment of mammalian cells with the proteasome inhibitor MG-132 results in the accumulation of polyubiquitinated proteasomal substrates. We found that endogenous BAG6 physically interacts with some MG-132-induced polyubiquitinated polypeptides (16) . Importantly, the BAG6-associated species of polyubiquitinated proteins disappeared when cells were co-treated with a protein synthesis inhibitor, implying that BAG6 targets newly translated defective polypeptides (16) . To further support this view, we showed that BAG6 physically interacts with puromycin-labelled aberrant nascent chain polypeptides in vivo (16) .
Defective nascent chain polypeptides tend to form insoluble and polyubiquitin-positive cytoplasmic aggregates (34, 35) . Our biochemical cell fractionation assay revealed that proteasome inhibition leads to the enfolding of endogenous BAG6 into insoluble fractions rich in polyubiquitinated defective polypeptides (16) . In accordance with this observation, The N-terminal 474 amino acids of human BAG6. This region is composed of Domains I and II, two independent hydrophobicity recognition domains, and contains five evolutionally conserved islands designated in this article as ECI1 to ECI5. Evolutionary conservation was determined by the sequence comparison of several BAG6 proteins derived from human, dog, mouse, fish and frog. Note that ECI1 corresponds exactly to the UBL sequence. (C) Multiple alignments of the C-terminal domain of BAG6 orthologues. Red box: conserved residues in BAG6 orthologues. Blue box: conserved residues between BAG1 and BAG6 (showing validity of BAG1BAG6 alignment). Red triangle: conserved residues in BAG-family proteins that were suggested to interact with Hsp70 (11, 12) . Note that C-terminal sequences of invertebrate BAG6 lose sequence similarity to BAG domains of BAG1 and vertebrates BAG6. HS, Homo sapiens (human); MM, Mus musculus (mouse); AC, Anolis carolinensis (lizard); XL, Xenopus laevis (frog); DR, Danio rerio (fish); CI, Ciona intestinalis (ascidian); DM, Drosophila melanogaster (fly); SP, Strongyrocentrotus purpuratus (sea urchin); NV, Nematostella vectensis (sea anemone); HM, Hydra magnipapillata (Hydra). (D) Phylogenic tree of UBL and BAG domains of BAG6 from various species. Note that sequence conservation of BAG domain in invertebrates is too poor to describe phylogenic analysis, in contrast to its high conservation in mammals. Blue, green and red colours BAG6 and protein quality control immunocytochemical analyses suggested that endogenous BAG6 associates with MG-132-induced polyubiquitin-positive inclusions known as 'aggresomes' (16, 34) . We also found that BAG6 co-localizes with puromycin-induced aggresome-like induced structures (ALIS) (16) , that are rich in incorrectly assembled nascent chain polypeptides (35, 36) . We also provided evidence that BAG6 controls in vivo formation of ALIS (16) . Taking into account that the BAG6 complex has the potential to stimulate polyubiquitination activity (16, 25, 37) , these observations suggest a crucial role for BAG6 in the ubiquitin-mediated metabolism of aggregation-prone nascent chain polypeptides in mammalian cells. In support of this idea, the highly unstable model defective polypeptide Luc163, a truncated luciferase that exposes hydrophobicity at its C-terminus, was recognized and polyubiquitinated by the BAG6 complex in rabbit reticulocyte lysates (16) . Wang et al. (25) showed that purified BAG6 is able to bind with heat-denatured, but not with native-folded, luciferase to prevent aggregation of denatured luciferase in vitro.
Ernst et al. (38) recently identified BAG6 as a cytosolic interactor of misfolded endoplasmic reticulum (ER)-derived protein. They enzymatically blocked UPS degradation by expressing UBXEBV WT, the catalytic domain of a ubiquitin-specific protease from the EpsteinBarr virus. From UBXEBV WTexpressing cells, they subsequently affinity retrieved interacting proteins of RI 332 , a misfolded glycoprotein used as a model to study the dislocation and degradation of ER-luminal proteins. MS analysis showed the specifically enriched association of BAG6 with the deglycosylated form of the misfolded protein. It should be pointed out that the misfolded protein was co-immunoprecipitated not only with BAG6 but also with the cytosolic chaperonine TRiC/CCT as well as ubiquitin ligase UBR4 (38) , opening the exciting possibility of their functional collaboration.
BAG6 in the Biogenesis of Tail-Anchored Transmembrane Proteins
In parallel to the earlier mentioned studies, Leznicki et al. (28) and Mariappan et al. (29) identified the BAG6 complex as a binding factor of tail-anchored (TA) protein in mammalian cells. The TA protein is a large family of transmembrane domain (TMD) polypeptides (functions of TA proteins include membrane biogenesis, apoptosis, vesicular trafficking and signal transduction etc.), characterized by an N-terminal cytosolic region anchored to the lipid bilayer by a single C-terminal TMD (39, 40) . As the members of this group do not contain a signal sequence at the N-terminus, the TMD emerges from the ribosome tunnel only after termination of translation. Accordingly, they must be inserted into the ER membrane by post-translational pathways, which is a distinct mechanism to that of most transmembrane proteins that are integrated mainly by the signal sequence and signal recognition particle (SRP)-mediated co-translational process (41) .
The molecular machinery for TA protein biogenesis was extensively studied in the budding yeast Saccharomyces cerevisiae. Yeast has a set of Get (Guided entry of tail anchored) proteins that are involved in a targeting pathway for ER-destined TA proteins (42, 43) . In the first step of this pathway, the chaperone-like protein Sgt2 captures the hydrophobic TMD of TA proteins (Fig. 3B ). Subsequently, Get4 and Get5 facilitate Get3TA protein complex formation by tethering Sgt2 with Get3 (32, 40, 4245) . TA proteins are then transferred from Get3 to the ER-resident receptor proteins Get1/Get2, and finally inserted into the ER membrane (30, 32) (Fig.  3B ). Mammalian homologues of Get components are also responsible for TA protein biogenesis (29, 4650) ( Fig. 3A) .
It has recently been shown that mammalian BAG6 associates with not only client TA protein but also TMD recognition complex 40 (TRC40), TRC35 and Ubl4a, the mammalian homologues of Get3, Get4 and Get5, respectively (25, 28, 29) . They showed that BAG6 complex captures the C-terminal transmembrane (and thus hydrophobic) domain of TA proteins that are newly released from ribosomes and transfers them to TRC40 (Fig. 3A) . Depletion of BAG6 resulted in failure of the TRC40 interaction with TA proteins causing mislocalization of TA proteins, which is analogous to the deletion of Get pathway genes in yeast (29) . BAG6 was also thought to aid transition of an open to closed TRC40 conformation (29) . These observations indicate that BAG6 plays a key role in TA protein biogenesis prior to TRC40-mediated insertion and that the BAG6 complex acts as a TMD-selective chaperone preventing TA proteins from inappropriate aggregation after their ribosomal release. Thus, the BAG6 complex determines the fate of nascent TA proteins (25, 26, 29, 30) .
The molecular functions of TRC35 and Ubl4a in mammalian TA protein biogenesis remain unclear. Structural differences between TRC35 and Get4, as well as between Ubl4a and Get5, suggest a distinct mechanism of TA protein assembly in mammals and yeast (44, 45, 5154) . For example, TRC35 lacks a b-hairpin structure between a11 and a12 helices that prevents the addition of the following helix pair (a13-a14) and is stabilized in the Get4 and Get5 complex (44, 51) . Second, Ubl4a lacks an N-terminal motif that is responsible for Get4 interaction and C-terminal extension, which is necessary for Get5 dimerization (52, 53) . Although yeast lacks a BAG6 homologous gene (30, 48) , mammalian BAG6 interacts with SgtA (22, 55), a mammalian homologue of yeast Sgt2, suggesting that the BAG6/SgtA complex might have a similar function to Sgt2 in yeast. Indeed, it has been suggested that, like yeast Sgt2, BAG6 itself captures and shields the hydrophobic TMD of TA proteins (25; Tanaka, H., unpublished data). Considering the differences between mammalian and yeast Get pathway components (Fig. 3A and B) , support of TA protein assembly might differ between mammals and yeast. BAG6 likely plays a role as a scaffold for the formation of a mammalian counterpart of the Get complex as well as a molecular chaperone. It is worth noting that the roles of Get/TRC components in mammals may not be restricted to TA protein biogenesis, especially in collaboration with BAG6 (25, 26) (Fig. 3A) . These proteins may have other crucial functions in protein quality control. In addition, it was reported that BAG6 tags TA proteins for degradation in the absence of TRC40 (26) , suggesting that BAG6 possesses the potential to determine the fate of misassembled TA proteins.
GET or ERAD: BAG6 Complex Acts as a Triage in Determining the Destiny
Protein folding and translocation to the ER are not sufficiently efficient. For example, it was estimated that ER-targeting efficiency of the newly synthesized ER-destined polypeptides varies from 60% to 95%, depending on the properties of the ER signal sequence (56, 57) . Newly synthesized proteins that fail to be targeted in the ER lumen or acquire their native conformation are subsequently translocated and degraded by the cytosolic proteasome (58, 59) . This process is known as ER-associated protein degradation (ERAD), a major protein quality control machinery in eukaryotic cells (6062). ERAD is essential for maintaining homeostasis in the transmembrane and secretory proteins by preventing the accumulation of defective polypeptides (63) , and employs a variety of chaperones that A B Fig. 3 Speculative model of BAG6-mediated protein quality control in mammalian cells. (A) BAG6 appears to couple translation, membrane protein assembly and protein degradation by forming a huge complex with TRCs, chaperones and ubiquitination machinery. Newly synthesized TA and other client polypeptides with exposed hydrophobocity were posttranslationally recognized by the BAG6 complex. If TA proteins are successfully transferred from BAG6 to its associated components such as TRC40, insertion and assembly into the ER membrane will succeed. If handoff fails within the appropriate time window, client proteins are targeted to ubiquitination (by unidentified E3 ubiquitin ligases) and are induced to be released into the proteasome for degradation. In the case of degradation deficiency, either pathologically induced or artificially induced by proteasome inhibition, BAG6 and its client proteins are destined for deposition into the aggregates, and thus forming an ubiquitin-positive aggresome or ALIS. Thus, BAG6 might be a dynamic platform protein for tethering nascent polypeptides with exposed hydrophobicity and downstream TRC35/TRC40 or degradation machinery, determining the fate of their client proteins. Note that many of these components are likely to form a dimer (or multimer), although they are described here as a monomer for simplicity. (B) Get pathway dedicated for TA protein assembly in budding yeast. C-terminal hydrophobicity (TMD) of newly synthesized TA proteins is directly recognized by Sgt2. Subsequently, the Get4 and Get5 complex appears to regulate the TA protein substrate handoff from Sgt2 to the downstream ATPase Get3. Get3 then transfers its substrates to the ER-resident receptor protein Get1/Get2 complex to stimulate insertion into the ER membrane.
BAG6 and protein quality control selectively recognize terminally misfolded proteins in the ER carrying exposed hydrophobic regions. Wang et al. (25) recently identified BAG6 as a binding partner for ER-resident and ERAD-dedicated E3 ubiquitin ligase gp78. Indeed, BAG6 acts to increase ERAD efficiency, because its depletion had a strong inhibitory effect on ERAD (25) . They provided evidence that the degradation of single-spanning transmembrane protein T-cell receptor (TCRa), a model ERAD substrate whose degradation requires gp78, is greatly impaired in BAG6-knockdown cells, whereas the degradation of a cytosolic proteasome substrate (Ub-V-GFP) was largely unaffected (25) . Stabilization of misfolded ER proteins was also observed when TRC35 and Ubl4a were individually knocked-down, supporting the idea that BAG6 acts in conjunction with these two BAG6 cofactors to increase ERAD efficiency (25) . BAG6 is capable of maintaining retrotranslocated ERAD substrates containing exposed aggregation-prone motifs in an unfolded yet soluble state, and delivering them to the UPS degradation machinery. Thus, it was suggested that the BAG6 complex promotes quality control of newly synthesized polypeptides in mammalian cells.
As described previously, BAG6 shields the hydrophobic TMD of TA proteins just after their ribosomal release and leads to the TA protein to ER insertion (28, 29) . It was subsequently suggested that the BAG6 complex has a broader specificity in binding with hydrophobic regions such as signal sequences and GPI-anchoring signals in a variety of mislocalized membrane proteins (25, 26) . Hessa et al. (26) postulated an interesting concept that the BAG6 complex acts as a triage factor that transfers only appropriately assembled TM proteins to the post-translational Get pathway and endorses the remainder (including mislocalized proteins) for degradation by the BAG6/ proteasome-mediated degradation pathway. It was also shown that BAG6 is recruited to the site of substrate dislocation through its interaction with a probable ER dislocon protein, Derlin2, which facilitates the passage of misfolded ER proteins to the cytoplasm (27) . Indeed, when proteasome is inhibited, BAG6 forms a complex with both the degradation substrates and Derlin2. Furthermore, BAG6 is also required to complete the dislocation reaction itself (25) . Claessen and Ploegh (27) also showed that the dislocon substrate TCRa stabilized inside the ER following BAG6 depletion, suggesting that BAG6 is required for exit from the ER and prevents a blockade induced by the exposed hydrophobic domains of TCRa. These reports together support the idea that BAG6 and its associated proteins provide an essential quality control system for transmembrane substrates and newly synthesized polypeptides with exposed hydrophobic stretches, and that they are primary targets of the BAG6 complex, some of which are targeted to the ERAD-and/or proteasome-mediated protein degradation pathway.
Defective Ribosomal Products: A Possible Link with BAG6 and Antigen Presentation
It has been shown that degradation products of proteasomes are the main source of peptide ligands presented on cell surface MHC class I molecules (64, 65) . However, there was a paradox that some viral proteins whose degradation products are presented on MHC as antigens are proteasome-resistant and highly stable proteins. Yewdell et al. (66, 67) resolved this conflicting issue by presenting the idea that the majority of antigenic peptides are derived from unstable nascent polypeptides that emerge from the ribosome into the cytosol. They designated the misfolded nascent polypeptides as defective ribosomal products (DRiPs). In accordance with their idea, inhibitors of proteasomes and protein synthesis decrease the cell surface presentation of endogenous antigens derived from long-lived, proteasome-resistant substrates in their mature forms (68) . It was also reported that some of MHC class I-restricted epitopes contain an unprocessed cleavage site of the ER signal peptidase (57) , implying that antigen processing of ER-targeted proteins by proteasomes occurs, at least in part, prior to translocation into the ER lumen. Thus, a cytosolic pathway of class I antigen-processing relies on the failure of ER-targeted proteins to reach their final destination (i.e. they could be bona fide mislocalized proteins).
The mechanisms by which DRiPs convert to MHC class I-restricted peptides have not been adequately elucidated. Recently, Huang et al. (69) showed that ablation of the N-terminal signal sequence from interleukin-2 receptor (IL-2Ra) resulted in mistargeting of this polypeptide to the cytosol as a result of SRP engagement failure. Mislocalized IL-2Ra shows increased susceptibility for proteasomal degradation and enhanced presentation of MHC class I-restricted peptides, whereas elimination of the C-terminal TMD abolishes these effects (69) . Such observations suggest that unembedded (and thus mislocalized) hydrophobicity of nascent proteins acts as a degron and thus stimulates the antigenic peptide supply. So, the next question is how are orphaned hydrophobicity targeted to proteasomes? BAG6 is encoded in the MHC region (10), but its function in immunity had proved enigmatic. Considering that BAG6 is essential for the proteasome-mediated degradation of nascent polypeptides that expose hydrophobicity, derived from either general misfolded proteins (16) or mislocalized transmembrane proteins (26) , it is likely to be central to the process of antigen production. Indeed, we showed that BAG6 knockdown resulted in partial suppression of MHC class I cell surface presentation (16) , suggesting that BAG6-mediated processing of newly synthesized proteins might be a source of peptide ligands for MHC class I molecules. Simultaneously, BAG6 might contribute to the process of transmembrane protein assembly (including that of the MHC class I molecule itself) that is necessary for antigen presentation.
BAG6 was previously suggested to be a proteasomeassociated protein (33) , especially under conditions of proteasome inhibition (16) . Considering that BAG6 is a fairly stable UBL protein in vivo, it should not be considered a substrate, but rather a functional collaborator of proteasomes. Our recent comprehensive MS analyses of human BAG6 confirmed that essentially all 26S proteasome subunits can be identified in BAG6 immunoprecipitates with high confidential scores (Hatta, T., and Natsume, T., personal communications). We also found that BAG6 associates with interferon-g (IFN-g)-induced immunoproteasomes (16) , which seem more proficient at producing peptides favoured by MHC class I molecules (70) . Recently, Ka¨mper et al. (71) showed that BAG6 expression is enhanced by IFN-g exposure. Accordingly, an intimate collaboration of BAG6 with immunoproteasomes, and possibly with thymoproteasomes (72) , in the control of antigen presentation is plausible, although this requires direct experimental corroboration.
Possible Links between BAG6 and Human Pathogenesis
The importance of protein quality control is exemplified by a number of human disorders. As aggregated proteins with polyubiquitin have been proposed to be central to the pathology of a number of protein misfolding diseases including neurodegenerative disorders (4, 8, 7375) , understanding the mechanisms of co-translational degradation of aggregation-prone proteins should be of primary importance. In addition, the recent understanding of the roles of BAG6 on membrane protein metabolism is particularly suggestive to a link with human pathogenesis, because a number of human diseases are known to link with the dysfunction of transmembrane proteins. It was reported that BAG6 regulates the steady state level of the single-membrane spanned ERAD substrate protein CD4 (25) , which is essential for T-cell function. Moreover, BAG6 interacts with transforming growth factor-b receptors and modulates their downstream signalling (20) , as well as being involved in BMP signalling (21) . We suspect that many, if not all, of the diverse functions of BAG6 thus far reported can be interpreted through the BAG6-mediated control of transmembrane proteins biogenesis and degradation, the possibility that remains to be proved in future study.
A recent breakthrough regarding the role of BAG6 in human diseases came from the examination of the single-spanning transmembrane protein, Tim-3 (T-cell immunoglobulin and mucin domain-containing molecule-3) (24). Tim-3 is highly expressed on exhausted CD4þ T cells in tumour-bearing individuals, and represses the T-cell response as a negative regulator in immune functions. 'Exhausted' T cells fail to exert effector functions such as cytotoxicity and cytokine secretion in response to antigen stimulation (76) , whereas suppression of Tim-3 restores the function of these T cells. Furthermore, defective Tim-3 expression causes autoimmunity by over-stimulating the capacity of regulatory T cells, whereas boosting Tim-3 signals can reverse this (76) . Consequently, understanding the molecular mechanisms modulating Tim-3 expression levels is critical for cancer immunology and in preventing autoimmune diseases such as allergic encephalomyelitis and type 1 diabetes.
Importantly, Rangachari et al. (24) reported that BAG6 binds with and suppresses the expression of Tim-3. Indeed, when BAG6 was retrovirally overexpressed in helper T cells, cell surface Tim-3 was reduced, the appearance of exhausted T cells prevented and instead an earlier onset of experimental autoimmune encephalomyelitis developed (24) . Thus, BAG6 overexpression promotes helper T-cell responses. By contrast, BAG6-deficient T cells expressed higher amounts of Tim-3 with a lower frequency of IFN-g-production, and induced many of the similarities in the phenotype of 'exhausted' T cells (24) . These observations suggest that BAG6 acts as a repressor of Tim-3-dependent T-cell exhaustion. Thus, manipulation of the interaction between BAG6 and Tim-3 could be a promising strategy in autoimmune and cancer therapy. BAG6 binds to the tail of Tim-3, and the extracellular ligand Galectin-9 disrupts this interaction by inducing phosphorylation of the Tim-3 tail at Tyr256 and Tyr263 (24) . In contrast, increasing hydrophobicity by replacement of these two tyrosines with phenylalanine greatly stimulated BAG6 binding of Tim-3 (24) . Clarification of the mechanism of BAG6-mediated reduction of Tim-3 is necessary to understand these processes.
Polymorphisms in the BAG6 locus have been linked to an increased incidence of lung cancer (77) and type 1 diabetes (78) . In addition, diseases such as thymus hyperplasia, myasthenia gravis and several adverse drug reactions are linked to the BAG6/BAT3 locus (79) , implying functional connections between BAG6, cancer immunology and autoimmune disorders. Elucidation of the involvement of BAG6 in the regulation of viral infections, cancer progression, autoimmune disorders and/or the onset of neurodegenerative diseases is therefore an important challenge to understand the contribution of BAG6 complexes in the pathogenesis of various human diseases. Indeed, we believe that the study of BAG6 is likely to provide insights into basic pathomechanistic principles that could be exploited for therapeutic purposes.
BAG6 Anatomy: A Multi-Domain Complex that May Provide a Platform for Protein Destruction
Primary sequence of BAG6 protein can be conceptually sub-divided into three distinctive parts: (i) an N-terminal region with amino acids 1474 that contains a UBL domain followed by several evolutionally conserved islands (tentatively designated ECI regions, Fig. 2A and B) ; (ii) a central proline-rich region with amino acids 4751,029 of unknown function ( Fig. 2A) and (iii) a C-terminal stretch with amino acids 1,0301,132 that contains nuclear localization signals (NLS) and a BAG domain ( Fig. 2A and C) .
Recent studies elucidated the potential functions in both N-terminal and C-terminal ends, and this section will summarize the detailed understanding about these points at this moment.
N-terminal region with a UBL domain
The original paper of Banerji et al. (10) suggested that BAT3/BAG6 contains 'single' UBL domains at its N-terminus ( Fig. 2A and B) . Indeed, our multiple alignments of BAG6 N-terminal residues revealed an evolutionary conserved island (ECI1) that corresponds exactly to the UBL domain (Fig. 2B) , indicating the likely vital function of this region. Hessa et al. (26) recently showed that the UBL domain is essential for recruiting ubiquitination machinery to BAG6 substrates, because the absence of a UBL domain resulted in the failure of in vitro ubiquitination of a model mislocalized protein (26) . Wang et al. (25) also reported that the UBL domain is necessary to bind with the ER-resident E3 ubiquitin ligase gp78, which is crucial for ERAD progression (61, 62) . Thus, it is probable that the UBL domain of BAG6 is functionally linked with ER-related protein quality control events.
We previously reported that Xenopus BAG6 contains two distinct regions within N-terminal 436 residues (the region corresponding to the N-terminal 474 amino acids of human BAG6), designated Domain I and Domain II ( Fig. 2A and B) (33) . Both domains possess a redundant ability to bind with the hydrophobic stretch of Rpn10c in vivo (33) . Domain I (residues 1216 in human BAG6) contains a typical UBL domain (residues 1792) at its N-terminus (Fig. 2B ) and the UBL domain is indispensable but not itself sufficient for affinity with hydrophobicity (33) . Interestingly, the C-terminal half of Domain I (residues 126184) contains another ECI (designated as ECI2, Fig. 2B ) that is also essential but not itself sufficient for substrate binding (33) , indicating that both the UBL and ECI2 sequences collaborate together to recognize hydrophobicity. Importantly, our recent analyses provide evidence that the recombinant Domain I fragment directly recognizes hydrophobicity of CL1 degron, and that ECI2 is essential for this interaction (Tanaka, H., unpublished data). This suggests a molecular basis for substrate recognition by the BAG6 protein. Although we lack a complete understanding of Domain II, its primary sequence shows additional conserved islands (ECI3 to 5) (Fig. 2B) , and ECI3 contains some sequence similarity to ubiquitin (33) . As Domain II also recognizes hydrophobic stretches (33) , functional redundancy between Domains I and II might therefore be crucial for substrate discrimination by BAG6. Thus, structural understanding of this region is necessary to elucidate the mechanisms of hydrophobicity recognition by BAG6.
NLS stimulates a massive nuclear accumulation of BAG6
Hydrophobicity recognition by the ubiquitin machinery might also be important in the nucleus. For example, it was reported that small hydrophobic peptides function as degrons for San1, a nuclear quality control ubiquitin ligase in yeast (80) . San1 recognition is triggered by the exposure of as few as five contiguous hydrophobic residues, which defines the minimum window of exposed hydrophobicity required for nuclear protein degradation. Human homologues of yeast San1 system have not been identified (80) .
Both vertebrate and invertebrate BAG6 contain bipartite NLS within their highly conserved C-terminus (encoded by exon 23 in the human genome) (Fig. 2B  and C) . Indeed, immunocytochemical analysis reveals a nuclear presence of BAG6 (16, 25, 81, 82) , whereas site-directed mutagenesis of the NLS leads to complete nuclear exclusion of this protein (81) . Although most recent reports restrict the BAG6 function to the cytoplasm (16, 2527), its predominant nuclear localization implies that BAG6 possesses alternative nuclear function(s). It has not been elucidated whether BAG6 participates in protein quality control in the nucleus (Fig. 4) .
Ka¨mper et al. (82) recently suggested that cell type-specific alternative splicing of BAG6 transcripts correlate with cytosolic/nuclear localization of its products. For example, the B lymphoma cell line Raji expresses BAG6 variants lacking exon 11B and with exclusive cytoplasmic distribution, whereas HeLa cells express full-length BAG6 that shows both nuclear/cytoplasmic localization but a predominant nuclear distribution (82) . They subsequently showed that treatment with leptomycin B, a CRM1 inhibitor, stimulates nuclear localization of BAG6 variants lacking exon 11B. These observations indicate that 
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Protein quality control ? M L P s Fig. 4 Schematic of the emerging function of BAG6 and its collaborator proteins. BAG6 is essential for the protein quality control of aggregation-prone newly synthesized polypeptides. Potential substrates of BAG6 include TA and other TMD proteins, mislocalized proteins (MLP), defective ribosomal products (DRiPs), ERAD substrates, all of these are destined for correct assembly, ubiquitin-mediated degradation and/or cytoplasmic aggregate formation. BAG6 determines the fate of client proteins with its accessory factors by as yet unknown mechanisms. In addition, the nuclear functions of BAG6 remain elusive.
the nuclear export of BAG6 is mediated by the CRM1-dependent pathway, which is influenced by the presence of the exon 11B sequence (82) .
Interestingly, nuclear BAG6 was reported to form a complex with histone acetyltransferase p300/CBP and stimulate p300-mediated acetylation of p53 in a DNA damage response (83) . In addition, two independent reports suggest that nuclear BAG6 interacts with methyltransferases to regulate histone H3 dimethylation, which is crucial for controlling chromatin organization, gene expression and the DNA damage response (84, 85) . The nuclear functions of BAG6 might be a good prospect for the future understanding of diverged BAG6 phenotypes in its suppressed cells (Fig. 4) . Wang et al. (25) suggested that the binding of Get-component TRC35 with BAG6 masks its NLS and modulates the nuclear translocation of BAG6, implying that membrane protein biogenesis might be functionally linked to the nuclear localization of BAG6.
Unusual 'BAG' domain in the C-terminus of BAG6 BAG-family proteins are characterized by their C-terminal BAG domain, a conserved region that has been suggested to mediate direct interaction with the ATPase domain of Hsp70/Hsc70 molecular chaperones (8688). The co-chaperones of the BAG-family proteins are also reported to be involved in protein quality control (86, 88, 89) . Six BAG family members have so far been identified in mammals and shown to regulate, both positively and negatively, the function of Hsp70/Hsc70 (88). Thress et al. (11) identified a 'BAG' domain at the C-terminus of Xenopus Scythe/ BAG6, and shown to inhibits Hsp70 chaperoning activity in vitro. Although we also confirmed that BAG6 can bind with Hsp70 as shown previously (11, 16, 90) , we observed that the in vivo interaction between BAG6 and hsp70 is far weaker than with BAG1. Thus, it is not clear how this domain contributes to hsp70 control. The BAG6-specific functions of the BAG domain in TA protein assembly, DRiPs metabolisms and ERAD have not been elucidated.
Multiple alignment of the BAG6 BAG domain from various species revealed some interesting aspects (Fig.  2C) . First, many residues that are necessary for hsp70 interaction and thus highly conserved within the BAG1 family (indicated by red arrowheads, Fig. 2C ) (11, 12) are substituted by alternative residues in mammalian BAG6. This indicates that the BAG6 BAG domain is atypical, and may explain the reduced affinity of BAG6 for hsp70 in vivo. Second, although amino acid sequences of BAG6 BAG domain are fairly well conserved within vertebrates (from fish to human, Fig.  2C ) and are particularly conserved in mammals, invertebrate BAG6 progressively diverges within the BAG domain (Fig. 2C) . In particular, most essential residues for hsp70-interaction are not present in the corresponding region of the invertebrate BAG6 BAG domain. Furthermore, inspection of available genomic sequences reveals that some invertebrates, such as the urochordata Ciona intestinalis, have lost the entire BAG domain stretch, despite the fact that upstream sequences including the NLS are highly conserved (Fig. 2C) . Third, phylogenetic trees of both UBL and BAG domains, at the N-and C-termini of BAG6 species, respectively, show a highly diverged shape (Fig.  2D) , implying that they have undergone distinct evolutionary pressure. Taken together, these findings suggest that the BAG domain of BAG6 possesses distinctive functions that are increasingly required for higher vertebrates. Elucidation of these points is necessary to understand the vertebrate-specific functions/ regulatory mechanisms for BAG6-mediated protein quality control machinery, especially in conjunction with the MHC-linked acquired immunity.
BAG6 as a core for multiple interacting protein complex Although the calculated molecular weight of BAG6 is 120 kDa, endogenous BAG6 was eluted from gel filtration with a molecular weight of 450 kDa (16) , suggesting that it undergoes in vivo oligomerization. In agreement with this hypothesis, in vitro analysis using recombinant Xenopus BAG6 N-terminus fragments suggests its multimerization (Kobayashi, M., unpublished data). The recent identification of several accessory factors, including TRC35 and Ubl4a, supports the idea that BAG6 functions as part (or the core) of a large complex in vivo (29) . Our preliminary observations indicate that the BAG6 complex is dynamic in vivo, because expression of aggregation-prone proteins led to the modification of BAG6-Ubl4a association. Furthermore, blockade of proteasomal degradation stimulates the formation of a supramolecular complex (MW of 2,000 kDa) containing BAG6, 26S proteasomes and several ubiquitininteracting proteins (16) , supporting the view that BAG6 is essential for ubiquitin-mediated degradation in vivo. Structural studies are now required to understand the assembly and regulation of such complexes. Reaper is an apoptotic inducer in the fruit fly that inhibits protein synthesis by binding directly to ribosomes (91), so Scythe was considered to be an apoptosis regulatory protein in vertebrates. Several studies support the idea that Scythe/BAG6/BAT3 is involved in apoptotic control in vertebrates (15, 18, 19, 37, 9295) . In a Xenopus cell-free system, depletion of endogenous BAG6 impedes Reaper-induced caspase activation, suggesting that BAG6 is necessary for the execution of Reaper-induced apoptosis (96) . On the other hand, the exogenous addition of excess wild-type BAG6 prevented the effect of Reaper (96), implying a possible suppressive effect of BAG6 on apoptosis. It is interesting to note that Reaper-independent apoptosis was induced by adding the N-terminally truncated form of BAG6 (lacking both Domains I and II) into the Xenopus eggs (17, 33, 37) . It is conceivable that the forced expression of C-terminal fragments enhanced a 'dominant negative' effect against the function of endogenous BAG6-binding proteins that are required for cell viability. Experimental verification of this idea is necessary in the future.
Previous genetic studies into the role of mammalian BAG6 in viability and apoptotic cell death show some conflicting results. Gene deletion of BAG6 in 129SvJ Â C57BL/6-derived mice resulted in neonatal lethality associated with widespread induction of aberrant apoptosis (15) , whereas BAG6 knockout mice with an ICR genetic background were viable, as reported by Sasaki et al. (83) . Considering that even a partial knockdown of BAG6 resulted in mitotic arrest with mislocalized chromosomes (22) and G1/S phase arrest in mammalian cultured cells (23) , the mechanisms of viability and fairly normal development of BAG6 knockout ICR mice is puzzling and suggests that BAG6 plays ambiguous, case-dependent roles in viability during mammalian development. Alternatively, redundant machinery might exist in parallel to compensate for the BAG6 function, which contributes to the complex phenotype of gene disruption studies. Sasaki et al. Several lines of evidence suggest that the ubiquitinproteasome dependent protein quality control pathway plays an essential function in apoptotic regulation (97) . Indeed, inhibition of this pathway induces gradual cell death concomitant with an accumulation of polyubiquitinated defective proteins. Our analysis indicated that BAG6 supports cell viability by eliminating the accumulation of cytotoxic defective polypeptides (16, 37) . Although BAG6 knockdown itself did not immediately affect cell viability, we found that it significantly enhanced the cytotoxicity of proteasome inhibitors (16) . Similarly, it accelerated puromycin-induced cell death (16) . These results indicate that BAG6 knockdown renders cells more susceptible to MG-132-and/or puromycin-induced death and that BAG6 offers a protective role against cell death through the accumulation of defective proteins in mammalian cells. Importantly, MG-132-induced cytotoxicity enhanced by BAG6 siRNA was suppressed by cycloheximide treatment (16) , supporting the idea that BAG6 prevents apoptosis, at least in part, by virtue of its ability to eliminate the accumulation of aggregation-prone nascent chain polypeptides. In accordance with this, Wang et al. (25) showed that depletion of BAG6 results in ERAD defects (ERAD being essential for the alleviation of ER stress to improve cell vitality, (98) ) in mammalian cells, suggesting an anti-apoptotic role of BAG6 in this occasion.
Finally, it should be pointed out that the N-terminal 471 residues of mouse BAG6 (corresponding to the N-terminal 474 residues of human BAG6) are both necessary and sufficient for binding to polyubiquitinated DRiPs (16) . Furthermore, this apparently corresponds to the region whose deletion induced apoptosis in Xenopus eggs (33, 37) . Taking into account the fact that the BAG6 N-terminus is necessary for interaction with both substrates and E3 ubiquitin ligases (16, 25, 26, 37) , these observations support the view that the N-terminal regions of Domain I and II are essential for the selective elimination of hydrophobicity-exposed nascent chain polypeptides. It was originally proposed that BAG6/Scythe sequesters an unknown apoptotic factor that is sufficient to induce apoptosis (96) . Now, we suspect that this apoptotic factor is a (variety of) defective aggregation-prone protein whose accumulation causes massive cell toxicity.
Future Prospects
A series of recent works suggested that BAG6 is an essential factor in the protein quality control of aggregation-prone nascent chain polypeptides (Fig. 4) , including a variety of newly synthesized transmembrane proteins (16, 2529) . One of the remaining questions is how BAG6 discriminates between potential substrates that are destined for correct assembly, degradation and/or aggregate formation, the latter two of which are alternative fates for folding-incompetent polypeptides (Fig. 4) . Hessa et al. (26) suggested that the length of the hydrophobic region is essential for BAG6 recognition, because both TA proteins and mislocalized membrane proteins possess long hydrophobic stretches. Mutagenesis experiments support this view and indicate that even modest reductions of TMD hydrophobicity curtail BAG6 interaction (29) . However, BAG6 apparently possesses an intrinsic affinity with CL1 degron and 10c-box polypeptides that contain shorter, less hydrophobic stretches compared with TMDs (16, 33) . We favour the idea that BAG6 complexes might contain multiple gateways (e.g. Hsp70, SgtA, the Domains I and II of BAG6) that support the recruitment of a variety of hydrophobic substrates and provide critical checkpoints to determine the final fates of respective polypeptides. It was also suggested that different ERAD substrates may have different levels of dependence on BAG6 function for degradation. Wang et al. (25) postulated the existence of redundant systems with partially overlapping substrate specificity in the cell, although the identities of these have not been elucidated. We previously reported that the ribosomal elongation factor EF1A can associate with the BAG6 complex (37) , but the mechanisms of how the protein's biosynthetic and protein quality control machineries collaborate remain to be investigated. It is also unclear whether collaborations exist with other chaperones such as TRiC/CCT, how BAG6 determines the fate of client proteins with its accessory factors such as SgtA and Ubl4a (99, 100) , and what are the nuclear functions of BAG6. These points should form the next challenge to help understand the precise function of this enigmatic but 'decision making' multi-talented protein complex.
